{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T10:33:50Z","timestamp":1783420430495,"version":"3.54.6"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2013,1,24]],"date-time":"2013-01-24T00:00:00Z","timestamp":1358985600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2013,1,24]],"date-time":"2013-01-24T00:00:00Z","timestamp":1358985600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2013,8]]},"DOI":"10.1007\/s10637-013-9925-z","type":"journal-article","created":{"date-parts":[[2013,1,23]],"date-time":"2013-01-23T13:16:14Z","timestamp":1358946974000},"page":"959-966","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Phase I study of oral CP-4126, a gemcitabine derivative, in patients with advanced solid tumors"],"prefix":"10.1007","volume":"31","author":[{"given":"F. E.","family":"Stuurman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. E.","family":"Voest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Awada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. O.","family":"Witteveen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Bergeland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.-A.","family":"Hals","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Rasch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. H. M.","family":"Schellens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Hendlisz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,1,24]]},"reference":[{"issue":"3","key":"9925_CR1","doi-asserted-by":"publisher","first-page":"447","DOI":"10.2165\/00003495-199754030-00009","volume":"54","author":"S Noble","year":"1997","unstructured":"Noble S, Goa KL (1997) Gemcitabine. A review of its pharmacology and clinical potential in non-small cell lung cancer and pancreatic cancer. Drugs 54(3):447\u2013472","journal-title":"Drugs"},{"issue":"19","key":"9925_CR2","first-page":"4349","volume":"58","author":"JR Mackey","year":"1998","unstructured":"Mackey JR, Mani RS, Selner M, Mowles D, Young JD, Belt JA, Crawford CR, Cass CE (1998) Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines. Cancer Res 58(19):4349\u20134357","journal-title":"Cancer Res"},{"issue":"1","key":"9925_CR3","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/S1368-7646(02)00002-X","volume":"5","author":"AM Bergman","year":"2002","unstructured":"Bergman AM, Pinedo HM, Peters GJ (2002) Determinants of resistance to 2\u2032,2\u2032-difluorodeoxycytidine (gemcitabine). Drug Resist Updat 5(1):19\u201333","journal-title":"Drug Resist Updat"},{"issue":"3","key":"9925_CR4","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1016\/S0022-3565(24)37730-4","volume":"286","author":"T Burke","year":"1998","unstructured":"Burke T, Lee S, Ferguson PJ, Hammond JR (1998) Interaction of 2\u2032,2\u2032-difluorodeoxycytidine (gemcitabine) and formycin B with the Na\u2009+\u2009-dependent and -independent nucleoside transporters of Ehrlich ascites tumor cells. J Pharmacol Exp Ther 286(3):1333\u20131340","journal-title":"J Pharmacol Exp Ther"},{"issue":"Suppl 5","key":"9925_CR5","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1093\/annonc\/mdj941","volume":"17","author":"E Mini","year":"2006","unstructured":"Mini E, Nobili S, Caciagli B, Landini I, Mazzei T (2006) Cellular pharmacology of gemcitabine. Ann Oncol 17(Suppl 5):7\u201312","journal-title":"Ann Oncol"},{"issue":"4","key":"9925_CR6","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/S0026-895X(25)09518-5","volume":"38","author":"V Heinemann","year":"1990","unstructured":"Heinemann V, Xu YZ, Chubb S, Sen A, Hertel LW, Grindey GB, Plunkett W (1990) Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2\u2032,2\u2032-difluorodeoxycytidine. Mol Pharmacol 38(4):567\u2013572","journal-title":"Mol Pharmacol"},{"issue":"22","key":"9925_CR7","first-page":"6110","volume":"51","author":"P Huang","year":"1991","unstructured":"Huang P, Chubb S, Hertel LW, Grindey GB, Plunkett W (1991) Action of 2\u2032,2\u2032-difluorodeoxycytidine on DNA synthesis. Cancer Res 51(22):6110\u20136117","journal-title":"Cancer Res"},{"issue":"3","key":"9925_CR8","first-page":"533","volume":"52","author":"V Heinemann","year":"1992","unstructured":"Heinemann V, Xu YZ, Chubb S, Sen A, Hertel LW, Grindey GB, Plunkett W (1992) Cellular elimination of 2\u2032,2\u2032-difluorodeoxycytidine 5\u2032-triphosphate: a mechanism of self-potentiation. Cancer Res 52(3):533\u2013539","journal-title":"Cancer Res"},{"issue":"6","key":"9925_CR9","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S0090-9556(25)08805-1","volume":"20","author":"LA Shipley","year":"2006","unstructured":"Shipley LA, Brown TJ, Cornpropst JD, Hamilton M, Daniels WD, Culp HW (2006) Metabolism and disposition of gemcitabine, and oncolytic deoxycytidine analog, in mice, rats, and dogs. Drug Metab Dispos 20(6):849\u2013855","journal-title":"Drug Metab Dispos"},{"issue":"5 Suppl 10","key":"9925_CR10","first-page":"3","volume":"23","author":"W Plunkett","year":"1996","unstructured":"Plunkett W, Huang P, Searcy CE, Gandhi V (1996) Gemcitabine: preclinical pharmacology and mechanisms of action. Semin Oncol 23(5 Suppl 10):3\u201315","journal-title":"Semin Oncol"},{"issue":"8","key":"9925_CR11","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.ctrv.2010.04.005","volume":"36","author":"GL Banna","year":"2010","unstructured":"Banna GL, Collov\u00e0 E, Gebbia V, Lipari H, Giuffrida P, Cavallaro S, Condorelli R, Buscarino C, Tralongo P, Ferra\u00f9 F (2010) Anticancer oral therapy: emerging related issues. Cancer Treat Rev 36(8):595\u2013605","journal-title":"Cancer Treat Rev"},{"issue":"6","key":"9925_CR12","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1038\/nrc1369","volume":"4","author":"RS Kerbel","year":"2004","unstructured":"Kerbel RS, Kamen B (2004) The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 4(6):423\u2013436","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"9925_CR13","doi-asserted-by":"publisher","first-page":"385","DOI":"10.2217\/fon.11.11","volume":"7","author":"N Andr\u00e9","year":"2011","unstructured":"Andr\u00e9 N, Padovani L, Pasquier E (2011) Metronomic scheduling of anticancer treatment: the next generation of multitarget therapy? Future Oncol 7(3):385\u2013394","journal-title":"Future Oncol"},{"issue":"1","key":"9925_CR14","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1038\/sj.bjc.6605727","volume":"103","author":"KKY Cham","year":"2010","unstructured":"Cham KKY, Baker JHE, Takhar KS et al (2010) Metronomic gemcitabine suppresses tumour growth, improves perfusion, and reduces hypoxia in human pancreatic ductal adenocarcinoma. Br J Cancer 103(1):52\u201360","journal-title":"Br J Cancer"},{"issue":"3","key":"9925_CR15","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1158\/1535-7163.MCT-07-2122","volume":"7","author":"B Laquente","year":"2008","unstructured":"Laquente B, Lacasa C, Ginest\u00e0 MM, Casanovas O, Figueras A, Gal\u00e1n M, Ribas IG, Germ\u00e0 JR, Capell\u00e0 G, Vi\u00f1als F (2008) Antiangiogenic effect of gemcitabine following metronomic administration in a pancreas cancer model. Mol Cancer Ther 7(3):638\u2013647","journal-title":"Mol Cancer Ther"},{"issue":"11","key":"9925_CR16","doi-asserted-by":"publisher","first-page":"3477","DOI":"10.1158\/1078-0432.CCR-07-4521","volume":"14","author":"SA Veltkamp","year":"2008","unstructured":"Veltkamp SA, Jansen RS, Callies S et al (2008) Oral administration of gemcitabine in patients with refractory tumors: a clinical and pharmacologic study. Clin Cancer Res 14(11):3477\u20133486","journal-title":"Clin Cancer Res"},{"issue":"22","key":"9925_CR17","doi-asserted-by":"publisher","first-page":"6958","DOI":"10.1021\/jm901181h","volume":"52","author":"DM Bender","year":"2009","unstructured":"Bender DM, Bao J, Dantzig AH et al (2009) Synthesis, crystallization, and biological evaluation of an orally active prodrug of gemcitabine. J Med Chem 52(22):6958\u20136961","journal-title":"J Med Chem"},{"issue":"18","key":"9925_CR18","doi-asserted-by":"publisher","first-page":"6071","DOI":"10.1158\/1078-0432.CCR-11-0353","volume":"17","author":"SLW Koolen","year":"2011","unstructured":"Koolen SLW, Witteveen PO, Jansen RS et al (2011) Phase I study of Oral gemcitabine prodrug (LY2334737) alone and in combination with erlotinib in patients with advanced solid tumors. Clin Cancer Res 17(18):6071\u20136082","journal-title":"Clin Cancer Res"},{"issue":"35","key":"9925_CR19","doi-asserted-by":"publisher","first-page":"4632","DOI":"10.2174\/092986709789878229","volume":"16","author":"AD Adema","year":"2009","unstructured":"Adema AD, Bijnsdorp IV, Sandvold ML, Verheul HM, Peters GJ (2009) Innovations and opportunities to improve conventional (deoxy)nucleoside and fluoropyrimidine analogs in cancer. Curr Med Chem 16(35):4632\u20134643","journal-title":"Curr Med Chem"},{"issue":"3","key":"9925_CR20","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1007\/s10637-009-9377-7","volume":"29","author":"AM Bergman","year":"2011","unstructured":"Bergman AM, Adema AD, Balzarini J et al (2011) Antiproliferative activity, mechanism of action and oral antitumor activity of CP-4126, a fatty acid derivative of gemcitabine, in in vitro and in vivo tumor models. Invest New Drugs 29(3):456\u2013466","journal-title":"Invest New Drugs"},{"issue":"5","key":"9925_CR21","doi-asserted-by":"publisher","first-page":"1908","DOI":"10.1007\/s10637-011-9756-8","volume":"30","author":"AD Adema","year":"2012","unstructured":"Adema AD, Smid K, Losekoot N, Honeywell RJ, Verheul HM, Myhren F, Sandvold ML, Peters GJ (2012) Metabolism and accumulation of the lipophilic deoxynucleoside analogs elacytarabine and CP-4126. Invest New Drugs 30(5):1908\u20131916","journal-title":"Invest New Drugs"},{"issue":"2","key":"9925_CR22","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"E Eisenhauer","year":"2009","unstructured":"Eisenhauer E, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228\u2013247","journal-title":"Eur J Cancer"},{"key":"9925_CR23","unstructured":"Lilly E Gemzar 200\u00a0mg powder for solution for infusion, Gemzar 1000\u00a0mg powder for solution for infusion. Summary of Product Characteristics (SPC)"},{"issue":"5","key":"9925_CR24","doi-asserted-by":"publisher","first-page":"466","DOI":"10.2133\/dmpk.DMPK-12-RV-042","volume":"27","author":"T Fukami","year":"2012","unstructured":"Fukami T, Yokoi T (2012) The emerging role of human esterases. Drug Metab Pharmacokinet 27(5):466\u2013477","journal-title":"Drug Metab Pharmacokinet"},{"issue":"3","key":"9925_CR25","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1200\/JCO.1991.9.3.491","volume":"9","author":"JL Abbruzzese","year":"1991","unstructured":"Abbruzzese JL, Grunewald R, Weeks EA, D G, Adams T, Nowak B, Mineishi S, Tarassoff P, Satterlee W, Raber MN (1991) A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J Clin Oncol 9(3):491\u2013498","journal-title":"J Clin Oncol"},{"issue":"2","key":"9925_CR26","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1179\/joc.2007.19.2.212","volume":"19","author":"GJ Peters","year":"2007","unstructured":"Peters GJ, Clavel M, Noordhuis P, Geyssen GJ, Laan AC, Guastalla J, Edzes HT, Vermorken JB (2007) Clinical phase I and pharmacology study of gemcitabine (2\u2032, 2\u2032-difluorodeoxycytidine) administered in a two-weekly schedule. J Chemother 19(2):212\u2013221","journal-title":"J Chemother"},{"key":"9925_CR27","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/S0959-8049(12)72378-X","volume":"48","author":"FE Stuurman","year":"2012","unstructured":"Stuurman FE, Lolkema MPJ, Soetekouw PMMB, Rosing H, Mergui-Roelvink M, Beijnen JH, Voest EE, Van Tinteren H, Huitema ADR, Schellens JHM (2012) 581 an adaptive, 2-stage, phase 1 comparative pharmacokinetic and cardiac safety study of two intravenous formulations of CO-101 in patients with advanced solid tumors. Eur J Cancer Supp 48(supp 6):178","journal-title":"Eur J Cancer Supp"},{"issue":"8","key":"9925_CR28","doi-asserted-by":"publisher","first-page":"2415","DOI":"10.1158\/1535-7163.MCT-08-0137","volume":"7","author":"S Veltkamp","year":"2008","unstructured":"Veltkamp S, Pluim D, Van Eijndhoven MAJ, Bolijn MJ, Ong FHG, Govindarajan R, Unadkat JD, Beijnen JH, Schellens JHM (2008) New insights into the pharmacology and cytotoxicity of gemcitabine and 2\u2032,2\u2032-difluorodeoxyuridine. Mol Cancer Ther 7(8):2415\u20132425","journal-title":"Mol Cancer Ther"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-013-9925-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-013-9925-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-013-9925-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-013-9925-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T18:16:43Z","timestamp":1745950603000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-013-9925-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1,24]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,8]]}},"alternative-id":["9925"],"URL":"https:\/\/doi.org\/10.1007\/s10637-013-9925-z","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,1,24]]},"assertion":[{"value":"5 November 2012","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2013","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2013","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}